Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

MONALISA A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis

Coordinator
St. Anna Kinderkrebsforschung GmbH, Austria
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€7.2m
Total cost
€7.2m
Partners
25 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101137028

What the project is doing

In the project's own words, from its summary on CORDIS.

High-risk neuroblastoma accounts for 15% of cancer related-deaths in children. Half of the >1500 patients yearly diagnosed with neuroblastoma in the EU have high-risk disease, which will relapse or progress in half these cases after first-line treatment. Relapsed neuroblastoma is aggressive and often therapy-resistant. Monitoring for disease relapse and therapy response is crucial for the survival chance of these patients.

The current standard-of-care for monitoring are imaging technologies and bone marrow assessment, which are costly, invasive and a burden for children, who often require anesthesia. These drawbacks limit how often is monitored. More sensitive, less invasive and less toxic monitoring techniques are needed. The mutational spectrum often changes in recurring tumors, which may explain therapy resistance and provide additional druggable targets.

Imaging, however, provides no information about molecular characteristics. Liquid biopsy tests are minimally invasive, allow frequent sampling and sensitively detect tumor molecular markers in tumor-derived DNA and messenger RNA circulating in peripheral blood. MONALISA aims to close existing gaps and establish liquid biopsies as standard-of-care to monitor relapsed/refractory neuroblastoma, as a blueprint for other pediatric cancers.

Reliable, early assessment of molecular progression or relapse is the main aim of the pragmatic randomized clinical trial proposed in MONALISA. We develop a digital decision support tool to help oncologists use the new monitoring and apply patient-reported outcomes to integrate patient viewpoints and assess the effect of minimally invasive, liquid biopsy diagnostics on quality of life. We will establish whether events can be detected earlier using liquid biopsy monitoring, and whether better overall survival is enabled by earlier diagnosis and treatment interventions.

This essential step towards personalized medicine will support reliable disease monitoring under treatment. “This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”

Topics

Who is involved

OrganisationCityCountryRole
St. Anna Kinderkrebsforschung GmbHWienAustriaCoordinator
Ait Austrian Institute of Technology GmbHWienAustriaParticipant
Esd - Evaluation Software Development GmbHInnsbruckAustriaParticipant
Labdia Labordiagnostik GmbHWienAustriaThird party
Medizinische Universitat InnsbruckInnsbruckAustriaParticipant
Siopen Verein Zur Forderung Der NeuroblastomforschungWienAustriaParticipant
Interuniversitair Micro-Electronica CentrumLeuvenBelgiumParticipant
Siop EuropeBruxelles / BrusselBelgiumParticipant
Universiteit GentGentBelgiumParticipant
Vib VzwZwijnaarde - GentBelgiumAssociatedpartner
Fakultni Nemocnice Motol a HomolkaPraha 5CzechiaParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Geniko Nosokomeio Paidon Athinon I Agia SofiaAthinaGreeceParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainParticipant
Institut CurieParisFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Children's Health IrelandDublinIrelandParticipant
Istituto Giannina GasliniGenovaItalyParticipant
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Institute of Cancer Research: the Royal Cancer Hospital LbgLondonUnited KingdomAssociatedpartner
Solving Kids Cancer UK LtdLondonUnited KingdomAssociatedpartner
University of LeedsLeedsUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI